Biogen Inc. (BIIB) key performance indicators and operating metrics (16 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP Diluted Earnings Per Share | 3.57 USD_per_share | FY2026-Q1 |
| Free Cash Flow | 594M | FY2026-Q1 |
| Total Rare Disease Revenue | 557M | FY2026-Q1 |
| LEQEMBI Global In-Market Sales | 168M | FY2026-Q1 |
| Biosimilars Revenue | 182M | FY2026-Q1 |
| Multiple Sclerosis Product Revenue | 958M | FY2026-Q1 |
| Other Product Revenue | 55M | FY2026-Q1 |
| SKYCLARYS Global Revenue | 151M | FY2026-Q1 |
| LEQEMBI United States In-Market Sales | 86M | FY2026-Q1 |
| Non-GAAP Cost of Sales as a Percentage of Total Revenue | 20.00 percent | FY2025-Q3 |
| Contract Manufacturing, Royalty, and Other Revenue | 151M | FY2025-Q3 |
| Anti-CD20 Therapeutic Program Revenue | 494M | FY2025-Q3 |
| ZURZUVAE Revenue | 55M | FY2025-Q3 |
| Alzheimer's Collaboration Revenue | 43M | FY2025-Q3 |
Back to BIIB overview · BIIB earnings · BIIB holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.